EVQLV

EVQLV is an artificial intelligence company purpose-built for antibody scientists and life sciences organizations. By combining deep expertise in machine learning, computational biology, drug development, and software engineering, EVQLV transforms the pace, cost, and scale of antibody discovery. The company's mission is to accelerate the speed at which healing reaches those in need, making AI-driven antibody design more accessible than ever before.

At the core of EVQLV's offering is a proprietary computational platform that EVQLVes antibody discovery by generating diverse, fully-human antibodies. The platform is also accessible through Abtique.com, providing antibody scientists with a streamlined entry point into AI-powered discovery tools.

Core Technology and Platform Capabilities

• Proprietary AI-driven computational platform designed specifically for antibody discovery and design
• Generation of diverse, fully-human antibodies at scale
• Integration of machine learning, computational biology, and software engineering into a unified discovery workflow
• Designed to reduce the time and cost associated with traditional antibody discovery processes
• Technology accessible via Abtique.com for antibody scientists seeking an easy path to AI

Partnership and Collaboration Models

• Rescue of failing lead antibody programs through computational redesign
• De novo antibody design and discovery for novel targets
• Design of biodifferentiated antibodies derived from known antibody sequences
• Flexible engagement models built to address specific antibody design challenges faced by partners
• Technology developed with partner needs in mind, enabling customized solutions across a range of project types

EVQLV positions itself as the easiest path to AI for antibody scientists, offering both direct platform access and collaborative partnership opportunities to help life sciences organizations advance their therapeutic programs more efficiently.